ஜான்சன் உயிரியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Govt okays Johnson & Johnson vaccine - Zimbabwe Situation
zimbabwesituation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zimbabwesituation.com Daily Mail and Mail on Sunday newspapers.
China s Infliximab Market Investigation Report 2021-2025 - A Human-mouse Chimeric IgG1 Monoclonal Antibody Targeting Tumor Necrosis Factor (TNF-A)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
EMA backs active substance scale-up at Janssen s COVID-19 vaccine site in the Netherlands
biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.
Reading time 1 min Christian Fernsby ▼ | July 3, 2021
EMA’s committee for human medicines (CHMP) has approved a scale-up of the active substance manufacturing process at Janssen Biologics.
Europe Janssen
The plant, which is located in Leiden, the Netherlands, produces all active substance for the manufacture of the EU supply of COVID-19 Vaccine Janssen, the COVID-19 vaccine developed by Janssen-Cilag International.
The approved modifications to the Janssen Biologics B.V. facility include a newly constructed building, new equipment and the introduction of additional process optimizations. This will enable an increase of the active substance manufacturing capacity and frequency.
The site is expected to support the continued supply of COVID-19 Vaccine Janssen in the European Union. ■
COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants
Vaccination efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the culprit behind the coronavirus disease (COVID-19) pandemic, have commenced in most countries. SARS-CoV-2 genetic sequence data was shared through GISAID on 10 January 2020, and on 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19.
Currently, 18 vaccines are approved by a national regulatory authority for use by the public as of June 2021. As a result of the SARS-CoV-2 vaccines, the spread, severity, and death due to COVID-19 have significantly been reduced. Phase III trials have shown that several COVID-19 vaccines reduce symptomatic SARS-CoV-2 infections by as much as 95%.